Serum expression levels of microRNA-382‑3p, -598-3p, -1246 and -184 in breast cancer patients

Fu,Lun; Li,Zhaoyun; Zhu,Jie; Wang,Pan; Fan,Guangmin; Dai,Yuechu; Zheng,Zhibao; Liu,Yang

doi:10.3892/ol.2016.4582

Serum expression levels of microRNA-382‑3p, -598-3p, -1246 and -184 in breast cancer patients

Authors:
- Lun Fu
- Zhaoyun Li
- Jie Zhu
- Pan Wang
- Guangmin Fan
- Yuechu Dai
- Zhibao Zheng
- Yang Liu
View Affiliations

Affiliations: College of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang 325035, P.R. China, Taizhou Central Hospital, Taizhou, Zhejiang 318000, P.R. China, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China
Published online on: May 16, 2016 https://doi.org/10.3892/ol.2016.4582
Pages: 269-274

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of the present study was to investigate the serum levels of microRNA (miRNA/miR)-382-3p, -598-3p, -1246 and ‑184 in breast cancer patients and to assess their feasibility as biomarkers for breast cancer screening. Serum samples were obtained from 100 breast cancer patients and 40 age‑matched healthy control subjects in Taizhou Central Hospital (Taizhou, Zhejiang, China) between January 2013 and September 2014. The serum expression levels of miR‑382‑3p, ‑598‑3p, ‑1246 and ‑184 were determined by stem‑loop reverse transcription‑quantitative polymerase chain reaction. Receiver operating characteristic curves were drawn to evaluate the sensitivity and specificity of the serum miRNA expression levels for the screening of breast cancer. miR‑382‑3p and ‑1246 were significantly upregulated in the serum of the breast cancer patients, while miR‑598‑3p and ‑184 were significantly downregulated. The sensitivity and specificity to detect breast cancer were as follows: miR‑382‑3p, 52.0 and 92.5%; miR‑598‑3p, 95.0 and 85.0%; miR‑1246, 93.0 and 75.0%; and miR‑184, 87.5 and 71.0%, respectively. The expression levels of the four serum miRNAs were not correlated with the patients' clinical stage. In summary, miR‑382‑3p, ‑598‑3p, ‑1246 and ‑184 are all involved in the development of breast cancer, and are promising biomarkers for breast cancer detection.

View Figures

View References

1	Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM and Goss PE: Breast cancer in China. Lancet Oncol. 15:e279–e289. 2014. View Article : Google Scholar : PubMed/NCBI
2	Mishra S, Srivastava AK, Suman S, Kumar V and Shukla Y: Circulating miRNAs revealed as surrogate molecular signatures for the early detection of breast cancer. Cancer Lett. 369:67–75. 2015. View Article : Google Scholar : PubMed/NCBI
3	Carrington JC and Ambros V: Role of microRNAs in plant and animal development. Science. 301:336–338. 2003. View Article : Google Scholar : PubMed/NCBI
4	Chen H, Xu GZ, Zhao Y, Tian B, Lu H, Yu X, Xu Z, Ying N, Hu S and Hua Y: A novel OxyR sensor and regulator of hydrogen peroxide stress with one cysteine residue in Deinococcus radiodurans. Plos One. 3:e16022008. View Article : Google Scholar : PubMed/NCBI
5	Chen H, Huang LF, Hua XT, Yin L, Hu Y, Wang C, Chen W, Yu X, Xu Z, Tian B, et al: Pleiotropic effects of RecQ in Deinococcus radiodurans. Genomics. 94:333–340. 2009. View Article : Google Scholar : PubMed/NCBI
6	Bethke A, Fielenbach N, Wang Z, Mangelsdorf DJ and Antebi A: Nuclear hormone receptor regulation of microRNAs controls developmental progression. Science. 324:95–98. 2009. View Article : Google Scholar : PubMed/NCBI
7	Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, et al: MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
8	Ng EK, Wong CL, Ma ES and Kwong A: MicroRNAs as new players for diagnosis, prognosis and therapeutic targets in breast cancer. J Oncol. 2009:3054202009. View Article : Google Scholar : PubMed/NCBI
9	Zhu J, Zheng Z, Wang J, Sun J, Wang P, Cheng X, Fu L, Zhang L, Wang Z and Li Z: Different miRNA expression profiles between human breast cancer tumors and serum. Front Genet. 5:1492014. View Article : Google Scholar : PubMed/NCBI
10	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
11	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
12	Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, et al: Breast cancer version 3.2014. J Natl Compr Canc Netw. 12:542–590. 2014.PubMed/NCBI
13	Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, Benjamin H, Kushnir M, Cholakh H, Melamed N, et al: Serum microRNAs are promising novel biomarkers. PLoS One. 3:e31482008. View Article : Google Scholar : PubMed/NCBI
14	Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
15	Brase JC, Wuttig D, Kuner R and Sültmann H: Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer. 9:3062010. View Article : Google Scholar : PubMed/NCBI
16	Sun Y, Wang M, Lin G, Sun S, Li X, Qi J and Li J: Serum MicroRNA-155 as a potential biomarker to track disease in breast cancer. PLoS One. 7:e470032012. View Article : Google Scholar : PubMed/NCBI
17	Zhao FL, Hua GD, Wang XF, Zhang XH, Zhang YK and Yu ZS: Serum overexpression of microRNA-10b in patients with bone metastatic primary breast cancer. J Int Med Res. 40:859–866. 2012. View Article : Google Scholar : PubMed/NCBI
18	Zearo S, Kim E, Zhu Y, Zhao JT, Sidhu SB, Robinson BG and Soon PSh: MicroRNA-484 is more highly expressed in serum of early breast cancer patients compared to healthy volunteers. BMC Cancer. 14:2002014. View Article : Google Scholar : PubMed/NCBI
19	Si H, Sun X, Chen Y, Cao Y, Chen S, Wang H and Hu C: Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J Cancer Res Clin Oncol. 139:223–229. 2013. View Article : Google Scholar : PubMed/NCBI
20	Chan M, Liaw CS, Ji SM, Tan HH, Wong CY, Thike AA, Tan PH, Ho GH and Lee AS: Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res. 19:4477–4487. 2013. View Article : Google Scholar : PubMed/NCBI
21	Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, Tait JF and Tewari M: Blood cell origin of circulating microRNAs: A cautionary note for cancer biomarker studies. Cancer Prev Res (Phila). 5:492–497. 2012. View Article : Google Scholar : PubMed/NCBI
22	Zhao BS, Liu SG, Wang TY, Ji YH, Qi B, Tao YP, Li HC and Wu XN: Screening of microRNA in patients with esophageal cancer at same tumor node metastasis stage with different prognoses. Asian Pac J Cancer Prev. 14:139–143. 2013. View Article : Google Scholar : PubMed/NCBI
23	Walter BA, Valera VA, Pinto PA and Merino MJ: Comprehensive microRNA profiling of prostate cancer. J Cancer. 4:350–357. 2013. View Article : Google Scholar : PubMed/NCBI
24	Mar-Aguilar F, Mendoza-Ramírez JA, Malagón-Santiago I, Espino-Silva PK, Santuario-Facio SK, Ruiz-Flores P, Rodríguez-Padilla C and Reséndez-Pérez D: Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis Markers. 34:163–169. 2013. View Article : Google Scholar : PubMed/NCBI
25	Li S, Meng H, Zhou F, Zhai L, Zhang L, Gu F, Fan Y, Lang R, Fu L, Gu L and Qi L: MicroRNA-132 is frequently down-regulated in ductal carcinoma in situ (DCIS) of breast and acts as a tumor suppressor by inhibiting cell proliferation. Pathol Res Pract. 209:179–183. 2013. View Article : Google Scholar : PubMed/NCBI
26	Piepoli A, Tavano F, Copetti M, Mazza T, Palumbo O, Panza A, di Mola FF, Pazienza V, Mazzoccoli G, Biscaglia G, et al: Mirna expression profiles identify drivers in colorectal and pancreatic cancers. PLoS One. 7:e336632012. View Article : Google Scholar : PubMed/NCBI
27	Takeshita N, Hoshino I, Mori M, Akutsu Y, Hanari N, Yoneyama Y, Ikeda N, Isozaki Y, Maruyama T, Akanuma N, et al: Serum microRNA expression profile: MiR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Brit J Cancer. 108:644–652. 2013. View Article : Google Scholar : PubMed/NCBI
28	Chen J, Yao D, Li Y, Chen H, He C, Ding N, Lu Y, Ou T, Zhao S, Li L and Long F: Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. Int J Mol Med. 32:557–567. 2013.PubMed/NCBI
29	Sun Z, Meng C, Wang S, Zhou N, Guan M, Bai C, Lu S, Han Q and Zhao RC: MicroRNA-1246 enhances migration and invasion through CADM1 in hepatocellular carcinoma. BMC Cancer. 14:6162014. View Article : Google Scholar : PubMed/NCBI
30	Pigati L, Yaddanapudi SC, Iyengar R, Kim DJ, Hearn SA, Danforth D, Hastings ML and Duelli DM: Selective release of MicroRNA species from normal and malignant mammary epithelial cells. PLoS One. 5:e135152010. View Article : Google Scholar : PubMed/NCBI